Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks

SAN DIEGO, Feb. 13, 2019 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent protecting the method of producing genetically modified T cells with a high percentage of stem cell memory T cells (Tscm).

 

Read the full press releaseCompany website